Pharma News

Drinking carbonated beverages is associated with increased risk of fatal cardiovascular disease, a new Japanese study has found. The study in nearly 800,000 patients in Japan suggests that limiting consumption of carbonated beverages may be beneficial for health.

New research has found that practicing yoga improves physical and mental wellbeing of people living with arthritis. The findings were published in the Journal of Rheumatology.

In Europe and Asia  drug currently used for treating gallstone-related spasms has been found effective in preventing the onset of Type-1 diabetes in mice. Researchers believe that a similar treatment may be effective in preventing the autoimmune disorder in humans too. The study was published in the Journal of Clinical Investigation.

A team of US researchers has developed 3D-printed guide that regrow both the sensory and motor functions of complex nerves after injury. The study was published in the journal Advanced Functional Materials.

[adsense:336x280:8701650588]

Sun Pharmaceutical Industries Ltd. and Strides Arcolab Ltd. have entered into a definitive agreement related to erstwhile Ranbaxy’s ‘Solus’ and ‘Solus Care’ divisions operating in the central nervous system (CNS) segment in India.

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company's (NYSE: LLY) Jardiance® (empagliflozin) significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by 14 percent when added to standard of care in patients with type 2 diabetes (T2D) at high risk of CV events. There was a 38 percent reduction in CV death, with no significant difference in the risk of non-fatal heart attack or non-fatal stroke.

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana has ruled in the company's favor regarding infringement of the vitamin regimen patent for Alimta® (pemetrexed for injection).

Novartis announced today that Swissmedic has approved Entresto(TM) (sacubitril/valsartan), previously known as LCZ696, to reduce the risk of cardiovascular mortality and morbidity in patients with heart failure with reduced ejection fraction (HFrEF). Entresto will be available on prescription for adult patients whose condition is classified NYHA class II-IV and with an ejection fraction of 40% or less. It is administered in combination with other heart failure therapies as appropriate, in place of an ACE inhibitor or angiotensin receptor blocker.

New research suggests that bacteria residing in our skin may help fight infections caused by chancroid, a sexually transmitted disease (STD). The findings suggest that skin microbiome can influence the outcomes of a bacterial infection. The study was published in the journal mBio.

Scientists found that a novel chocolate made of dietary cocoa extract can promote brain health in the elderly. The paper was published in the Journal of Alzheimer's Disease.